ArticleTurkish journal of medical sciences2026
C-reactive protein-albumin-lymphocyte (CALLY) index as a novel inflammatory marker for sarcopenia: evidence from a cross-sectional study.
Article in Turkish journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Sarcopenia is a geriatric syndrome characterized by progressive impairments in skeletal muscle mass and performance, with chronic low-grade systemic inflammation playing a pivotal role in its development. The C-reactive protein-albumin-lymphocyte (CALLY) index reflects inflammatory burden alongside immune and nutritional status; however, its association with sarcopenia in older populations has yet to be sufficiently elucidated. The present study investigates the relationship between CALLY index values and probable sarcopenia (PS) in a large cohort of geriatric outpatients. Materials and methods: Included in this retrospective cross-sectional study were 2042 geriatric outpatients aged ≥65 years who were assessed between May 2022 and March 2025. PS was defined based on EWGSOP-2 criteria (handgrip strength or chair stand test), while sarcopenia risk was assessed using the SARC-F questionnaire (assessing strength, assistance with walking, rise from a chair, climb stairs, and falls). The CALLY index was calculated based on comprehensive geriatric assessment results and laboratory parameters. A complete case analysis was performed and patients with incomplete data were excluded. Group comparisons, logistic regression, ROC curve analyses, and correlation analyses were performed. Results: Of the participants, 1092 (53.5%) were classified as PS and 950 (46.5%) as normal. Lower CALLY index values were observed in those with PS and high SARC-F scores (p <0.001), and were independently associated with both PS and sarcopenia risk in logistic regression analysis. In addition, the CALLY index was negatively correlated with SARC-F, timed up and go, chair stand test, and 4-meter walking time, and positively correlated with handgrip strength (all p <0.001). Conclusion: Lower CALLY values were independently associated with both PS and sarcopenia risk among older adults, supporting its use as a practical and accessible biomarker alongside routine geriatric assessment. Due to the cross-sectional nature of the study, further prospective studies involving a larger cohort are necessary to verify these associations and to assess prognostic utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.